65,437 trials
Low Bone Mass · Low Bone Mineral Density · Osteoporosis
Primary: Percent Change From the Parent Study Baseline in Cortical Thickness at the Distal Radius by HR-pQCT — -5.5; -1.8 Percent change — p=0.0766
Cystocele · Uterine Prolapse · Urinary Incontinence
Primary: Recurrent Stage II or Greater Anterior Vaginal Prolapse — 24; 11 participants — p=0.005
Persistent or Permanent Non-valvular Atrial Fibrillation
Primary: Premature Discontinuation of Study or Study Drug Due to Any Reason — 4; 6; 3 Participants
Smoking Cessation
Primary: Percentage of Participants With Smoking Abstinence at Week 12 — 46.40 percentage of participants
Ulcerative Colitis
Primary: Percentage of Treatment Success Patients at Week 6, ITT (Intent to Treat) Population — 59.2; 71.8 Percentage of Participants — p=0.0357
Cataract
Primary: Posterior Capsule Opacification (PCO) — 0.18; 0.15 Units on a scale
Bipolar Disorder
Primary: Number of Participants With Any Serious Adverse Event (SAE) and Any Non Serious Adverse Event — 13; 75 participants
Plasmodium Falciparum Infection
Primary: Number of Clinical Malaria Episodes Per Year of Follow-up — 0.61; 0.68; 0.64; 0.59 Episodes per PYAR — p=0.8097
Influenza
Primary: Number of Participants With Reactogenicity (Solicited) Adverse Events (AEs) — 40; 62; 12; 15 participants
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Number of Participants Who Achieved a Confirmed Response (CR), Very Good Partial Response (VGPR) or Partial Response (PR) During Treatment — 28; 16 participants
Sarcoma
Primary: Proportion of Patients Who Achieve a Clinical Response — 0.33 proportion
Alcohol Withdrawal Delirium
Primary: Benzodiazepine Doses Used to Treat Acutely-withdrawing Alcoholic Patients in the Baclofen-treated and Placebo-treated Groups — 14.1; 124.4 mg of benzodiazepine per 8 hours
Bacterial Infections · Eye Infections
Primary: Assessment of Pharmacokinetic Parameters
Alzheimer's Disease
Primary: Percentage of Patients Who Achieved and Maintained the Maximum Dose of 10 cm^2 Rivastigmine Patch for at Least 8 Weeks During 24 Weeks Study — 70.6 Percentage of…
Skin Manifestations
Primary: Number of Participants Who Were a Success With Regard to Worst Post-baseline Tolerability Assessment Scores in Each Assessment (Erythema, Scaling, Dryness…